Proteomics in Pharmaceutical Research and Development

Cutler, Paul; Birrell, Helen; Haran, M.; Man, Wai J.; Neville, Bill; Skehel, Mark; White, Ian R.

doi:10.1042/bst027a069

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Put another way, proteomics provides a very powerful means of revealing epigenetic effects, i.e., effects that involve multiple genes. At present proteomics is being applied most actively in pharmaceutical research and development (16,90) in two principal areas: drug discovery and target selection (e.g., via proteome difference analysis of pathogenic versus nonpathogenic organisms, normal versus dysfunctional states, and disruption of stress-induced protein synthesis) and drug mode of action, toxicological screening, and the monitoring of disease progression during clinical trials. The latter group of clinical features, which are directed at gaining a fuller understanding of pharmacological mechanisms of drugs, is driving the new field of pharmacoproteomics.…”

Section: Proteomicsmentioning

confidence: 99%

“…Present limitations and areas in need of improvement include the resolution and characterization of hydrophobic proteins which include major targets for pharmaceutical intervention (membrane enzymes and receptors) (90); quality of protein separation (368); ability to detect very low copy number proteins (226,451); and improved throughput and automation (90,226).…”

Section: Proteomicsmentioning

confidence: 99%

See 1 more Smart Citation

Search and Discovery Strategies for Biotechnology: the Paradigm Shift

Bull

Ward

Goodfellow

2000

Microbiol Mol Biol Rev

417

250

View full text Add to dashboard Cite

SUMMARY Profound changes are occurring in the strategies that biotechnology-based industries are deploying in the search for exploitable biology and to discover new products and develop new or improved processes. The advances that have been made in the past decade in areas such as combinatorial chemistry, combinatorial biosynthesis, metabolic pathway engineering, gene shuffling, and directed evolution of proteins have caused some companies to consider withdrawing from natural product screening. In this review we examine the paradigm shift from traditional biology to bioinformatics that is revolutionizing exploitable biology. We conclude that the reinvigorated means of detecting novel organisms, novel chemical structures, and novel biocatalytic activities will ensure that natural products will continue to be a primary resource for biotechnology. The paradigm shift has been driven by a convergence of complementary technologies, exemplified by DNA sequencing and amplification, genome sequencing and annotation, proteome analysis, and phenotypic inventorying, resulting in the establishment of huge databases that can be mined in order to generate useful knowledge such as the identity and characterization of organisms and the identity of biotechnology targets. Concurrently there have been major advances in understanding the extent of microbial diversity, how uncultured organisms might be grown, and how expression of the metabolic potential of microorganisms can be maximized. The integration of information from complementary databases presents a significant challenge. Such integration should facilitate answers to complex questions involving sequence, biochemical, physiological, taxonomic, and ecological information of the sort posed in exploitable biology. The paradigm shift which we discuss is not absolute in the sense that it will replace established microbiology; rather, it reinforces our view that innovative microbiology is essential for releasing the potential of microbial diversity for biotechnology penetration throughout industry. Various of these issues are considered with reference to deep-sea microbiology and biotechnology.

show abstract

Section: Proteomicsmentioning

confidence: 99%